Boundless Bio to Merge with Serapha Bio in $230M Deal, Pivoting from Oncology to Rare Disease — Boundless Bio, Inc.

Event summary

Boundless Bio (Nasdaq: BOLD) to merge with Serapha Bio in an all-stock deal, operating as Serapha Bio post-merger and trading under ticker 'AATD'.
$230M concurrent private placement co-led by RTW Investments and RA Capital Management, with participation from top healthcare investors.
Combined company to focus on SERP-01, an in vivo base editing therapy for Alpha-1 Antitrypsin Deficiency (AATD), targeting the SERPINA1 E342K mutation.
Boundless Bio stockholders expected to own ~3.7% of the combined company; pre-merger Serapha stockholders to own ~96.3%.
Transaction expected to close in Q4 2026, subject to regulatory approvals and shareholder votes.

The big picture

Boundless Bio's merger with Serapha Bio marks a strategic pivot from oncology to rare disease therapeutics, capitalizing on Serapha's lead program for AATD. The $230M private placement underscores investor confidence in the potential of SERP-01, which aims to address both liver and lung manifestations of the disease. This deal reflects a broader trend of biotech companies realigning portfolios towards high-impact, genetically targeted therapies.

What we're watching

Clinical Progress: The pace at which SERP-01 advances through Phase 2 and into Phase 3, given the combined company's runway into mid-2029.
Execution Risk: Whether Serapha can effectively transition from a private to a public platform while maintaining focus on AATD.
Market Dynamics: How the broader shift towards rare disease therapies impacts investor interest in the combined entity.